Professor_Bart
@bart_professor
Followers
2K
Following
2K
Statuses
2K
Professor Dr Bart Van Wijmeersch Neurologist, Immunologist #MultipleSclerosis Expert @ University MS Centre, Hasselt-Pelt, Belgium
Hasselt, Belgium
Joined March 2019
Je kan vanaf nu Afl. 12: MRI & AI bekijken en/of beluisteren op Youtube. Is er een verschil tussen #scanners ? Waarom moet je altijd onder dezelfde scanner gaan? Wat kan #ai hierin betekenen? Wordt een radioloog dan overbodig? @4nnsMiles
0
1
2
Best wishes for a wonderful 2025! May peace, love, good health and joy be your constant companions #happynewyear
0
0
1
What a big legacy, what a great researcher, what a great teacher, what a great visionary, what a great man… a true example and inspiration. We will miss you dearly. RIP 😔
E' mancato il Prof. Giancarlo Comi, un amico, un collega, un grande medico.
0
0
3
RT @ECTRIMS: Professor Giancarlo Comi stressed the importance of listening to individuals with MS, pointing out that their experiences are…
0
12
0
Ook voor #ectrims2024 Dag 3 overloop en verduidelijk ik kort de belangrijkste topics (met een mooie afsluiter) in een korte video.
0
0
2
RT @drbarrysinger: Lebrun-Frenay: Preventive healthcare in multiple sclerosis will need to focus on lifestyle and Epstein-Barr vaccination.…
0
11
0
Low anti-inflammatory effect of tolebrutinib but clear effect on disease progression… but many analysis are pending: why no effect on brain atrophy/why is the effect Gd+ lesions low/… Hopefully deep dive in the data will learn us more! 🤞🏻…let’s get on this 💪🏻
1
2
4
Jiwon Oh (US): tolebrutinib vs teriflunimode in RRMS (GEMINI trials). - ARR : no difference! - 6m CDW: 29% reduction on tolebr - 3m CDW: 27% reduction on tolebr - New Gd+ lesions are higher on tolebrutinib! - T2 lesions: no difference - good safety profile #ECTRIMS2024
0
9
40
Chataway (UK): MS-stat2 study on simvastatin 80mg vs placebo in SPMS. Large phase 3 trial, unfortunately no significant effect on confirmed progression 🤷🏻♂️ #ECTRIMS2024
0
4
4
Kowalec (US) effect of genetic predisposition for depression on disease activity in #MS. Higher risk of relapse and EDSS progression in persons with higher predisposition for depression! Importance of comorbidity on MS disease course! #ECTRIMS2024
0
3
9
Abdelhak: effect of fingolimod and anti-CD20 treatment on sGFAP (z-scores) evolution & subsequent effect on PIRA in RRMS pts. Lowering Z-GFAP in first two years of treatment decreases PIRA risk in subsequent years by 44 (aCD20)-55%(fingo) sNFL does not add effect #ECTRIMS2024
0
0
0
1. Unfortunately ‘measuring’ B cell tolerance defects is cumbersome and not readily available for the clinic 🤷🏻♂️ 2. Extending the interval of course has also other goals: decreasing infections risk (and treatment costs) f.e.
0
0
0
1. Per patient, the interval seems to be quite stable (f.e. 10months every time before repopulation in same patient) 2. Cutoff used for repopulation was 10cells/ml (0,01/mcl) abs count!
0
0
0
RT @bollo_luca: Excited to have just presented at #ECTRIMS2024 our work showing that thalamic atrophy at baseline predicts PIRA in early-MS…
0
9
0
Müller Jannis: MSBase register study in de-escalation of treatment in #MS. Increased risk of relapse reoccurring remains 2.3x higher. No real cutoff for age, EDDS, disease duration or time from last relapse was found. Note: Most were on natalizumab in this study! #ECTRIMS2024
1
3
10
